Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

CVS Caremark Takes Measured Approach In “Go To Market” Strategies

  • News

Executive Summary

CVS Caremark is in the process of introducing new "cross-functional" products and services to its health plan clients, CEO Thomas Ryan said during the firm's second quarter earnings call Aug. 2

You may also be interested in...



CVS Caremark Expanding Retail Access To Specialty Drugs

CVS Caremark is moving to increase its specialty drug sales with two new in-store services. The firm discussed the initiatives during its investor day presentation May 21

CVS Caremark Expanding Retail Access To Specialty Drugs

CVS Caremark is moving to increase its specialty drug sales with two new in-store services. The firm discussed the initiatives during its investor day presentation May 21

CVS Suit Against Prasco Illustrates Pricing Leverage From Caremark Merger

A lawsuit by CVS Caremark against generic drug manufacturer Prasco illustrates the potential cross-market leverage that the combined pharmacy/PBM entity is able to wield

Table

View full table

Tags:
Latest Headlines

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications

Industry & Regulators To Align Advice on COVID-19 Vaccine Updates

Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines

See All
UsernamePublicRestriction

Register

PS048643

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By